These differences have remarkable clinical implications, because on the one hand early epigenetic events might be used for early detection of tumours in the first cluster (by using quantitative DNA methylation markers in the bile of individuals at risk)80 and on the other hand, the tumour clonal mutations might be a marker of effective targeted therapies (such as IDH inhibitors). Here, IDH1 is linked to neoplasm.